Heartsciences INC 10-Q quarterly reports

HeartSciences Inc. reports progress on its AI-ECG platforms, secures significant financing, and addresses going concern issues in its Q3 2026 filing.

HeartSciences Inc. reported minimal revenue growth and continued net losses in its Q2 2026 filing, while advancing its AI-ECG technology and securing significant capital through equity offerings.

HeartSciences Inc. reports increased cash and equity from recent capital raises, advancing its AI-ECG technology and FDA submissions despite ongoing net losses and going concern doubts.

HeartSciences Inc. reports its Q3 2025 results, highlighting ongoing efforts to obtain FDA clearance for its MyoVista wav ECG device and addressing concerns about its ability to continue as a going concern.

HeartSciences Inc. released its second quarter 2025 results, highlighting ongoing efforts towards FDA submission for its MyoVista wav ECG device and the development of AI-ECG algorithms.

Heart Test Laboratories reports a net loss of $2.1 million for the third quarter of 2024, while progressing towards FDA submission for its MyoVista wav ECG device.

Heart Test Laboratories reports its Q3 2024 results, highlighting progress towards FDA clearance for its MyoVista device and development of AI-ECG algorithms.